| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9463160 | APRECIA PHARMS | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
Feb, 2018
(6 years ago) | |
| US6471992 | APRECIA PHARMS | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
Feb, 2018
(6 years ago) | |
| US9669009 | APRECIA PHARMS | Rapid disperse dosage form containing levetiracetam |
Mar, 2034
(9 years from now) | |
| US11160786 | APRECIA PHARMS | Rapid disperse dosage form |
Mar, 2034
(9 years from now) | |
| US9339489 | APRECIA PHARMS | Rapid disperse dosage form containing levetiracetam |
Mar, 2034
(9 years from now) | |
Spritam is owned by Aprecia Pharms.
Spritam contains Levetiracetam.
Spritam has a total of 5 drug patents out of which 2 drug patents have expired.
Expired drug patents of Spritam are:
- US9463160
- US6471992
Spritam was authorised for market use on 31 July, 2015.
Spritam is available in tablet, for suspension;oral dosage forms.
Spritam can be used as method of administering levetiracetam, method of administering levetiracetam under fasted conditions.
The generics of Spritam are possible to be released after 14 March, 2034.
Drugs and Companies using LEVETIRACETAM ingredient
Market Authorisation Date: 31 July, 2015
Treatment: Method of administering levetiracetam under fasted conditions; Method of administering levetiracetam
Dosage: TABLET, FOR SUSPENSION;ORAL
SPRITAM family patents
